{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:34:11Z","timestamp":1793406851818,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00428-023-03606-6","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T12:01:46Z","timestamp":1689940906000},"page":"145-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications"],"prefix":"10.1007","volume":"483","author":[{"given":"Chlo\u00e9","family":"Cammareri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Beltzung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Michal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Vanhersecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Coindre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Le Loarer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Vergier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2698-0249","authenticated-orcid":false,"given":"Raul","family":"Perret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"3606_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/s1074-7613(00)80426-4","volume":"6","author":"H Ikeda","year":"1997","unstructured":"Ikeda H, Leth\u00e9 B, Lehmann F et al (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199\u2013208. https:\/\/doi.org\/10.1016\/s1074-7613(00)80426-4","journal-title":"Immunity"},{"key":"3606_CR2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","volume":"122","author":"MT Epping","year":"2005","unstructured":"Epping MT, Wang L, Edel MJ, Carl\u00e9e L, Hernandez M, Bernards R (2005) The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122:835\u2013847. https:\/\/doi.org\/10.1016\/j.cell.2005.07.003","journal-title":"Cell"},{"key":"3606_CR3","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1182\/blood-2008-07-170282","volume":"114","author":"VG Oehler","year":"2009","unstructured":"Oehler VG, Guthrie KA, Cummings CL et al (2009) The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 114:3299\u20133308. https:\/\/doi.org\/10.1182\/blood-2008-07-170282","journal-title":"Blood"},{"key":"3606_CR4","doi-asserted-by":"publisher","first-page":"e000068","DOI":"10.1136\/esmoopen-2016-000068","volume":"1","author":"R Gutzmer","year":"2016","unstructured":"Gutzmer R, Rivoltini L, Levchenko E et al (2016) Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO Open 1:e000068. https:\/\/doi.org\/10.1136\/esmoopen-2016-000068","journal-title":"ESMO Open"},{"key":"3606_CR5","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1016\/j.jtho.2016.08.1206","volume":"11","author":"JL Pujol","year":"2016","unstructured":"Pujol JL, De Pas T, Rittmeyer A et al (2016) Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase I dose escalation study. J Thorac Oncol 11:2208\u20132217. https:\/\/doi.org\/10.1016\/j.jtho.2016.08.1206","journal-title":"J Thorac Oncol"},{"key":"3606_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamaophthalmol.2017.0729","volume":"135","author":"G Gezgin","year":"2017","unstructured":"Gezgin G, Luk SJ, Cao J et al (2017) PRAME as a potential target for immunotherapy in metastatic uveal melanoma. JAMA Ophthalmol 135:541\u2013549. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.0729","journal-title":"JAMA Ophthalmol"},{"key":"3606_CR7","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/his.14312","volume":"78","author":"SE Gradecki","year":"2021","unstructured":"Gradecki SE, Valdes-Rodriguez R, Wick MR, Gru AA (2021) PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna. Histopathology 78:1000\u20131008. https:\/\/doi.org\/10.1111\/his.14312","journal-title":"Histopathology"},{"key":"3606_CR8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/cup.14000","volume":"48","author":"AK Alomari","year":"2021","unstructured":"Alomari AK, Tharp AW, Umphress B, Kowal RP (2021) The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors. J Cutan Pathol 48:1115\u20131123. https:\/\/doi.org\/10.1111\/cup.14000","journal-title":"J Cutan Pathol"},{"key":"3606_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/pas.0000000000001393","volume":"44","author":"C Lezcano","year":"2020","unstructured":"Lezcano C, Pulitzer M, Moy AP, Hollmann TJ, Jungbluth AA, Busam KJ (2020) Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma. Am J Surg Pathol 44:503\u2013508. https:\/\/doi.org\/10.1097\/pas.0000000000001393","journal-title":"Am J Surg Pathol"},{"key":"3606_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.path.2021.01.001","volume":"14","author":"C Lezcano","year":"2021","unstructured":"Lezcano C, Jungbluth AA, Busam KJ (2021) PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions. Surg Pathol Clin 14:165\u2013175. https:\/\/doi.org\/10.1016\/j.path.2021.01.001","journal-title":"Surg Pathol Clin"},{"key":"3606_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/cup.13876","volume":"48","author":"SE Gradecki","year":"2021","unstructured":"Gradecki SE, Slingluff CL, Gru AA (2021) PRAME expression in 155 cases of metastatic melanoma. J Cutan Pathol 48:479\u2013485. https:\/\/doi.org\/10.1111\/cup.13876","journal-title":"J Cutan Pathol"},{"key":"3606_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/pas.0000000000001878","volume":"46","author":"G Santandrea","year":"2022","unstructured":"Santandrea G, Valli R, Zanetti E et al (2022) Comparative analysis of PRAME expression in 127 acral and nail melanocytic lesions. Am J Surg Pathol 46:579\u2013590. https:\/\/doi.org\/10.1097\/pas.0000000000001878","journal-title":"Am J Surg Pathol"},{"key":"3606_CR13","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/pas.0000000000001944","volume":"46","author":"M Kaczorowski","year":"2022","unstructured":"Kaczorowski M, Ch\u0142opek M, Kruczak A, Ry\u015b J, Lasota J, Miettinen M (2022) PRAME expression in cancer. a systematic immunohistochemical study of >5800 epithelial and nonepithelial tumors. Am J Surg Pathol 46:1467\u20131476. https:\/\/doi.org\/10.1097\/pas.0000000000001944","journal-title":"Am J Surg Pathol"},{"key":"3606_CR14","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/cup.13812","volume":"47","author":"SS Raghavan","year":"2020","unstructured":"Raghavan SS, Wang JY, Toland A et al (2020) Diffuse PRAME expression is highly specific for malignant melanoma in the distinction from clear cell sarcoma. J Cutan Pathol 47:1226\u20131228. https:\/\/doi.org\/10.1111\/cup.13812","journal-title":"J Cutan Pathol"},{"key":"3606_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/his.14814","volume":"82","author":"YP Chen","year":"2023","unstructured":"Chen YP, Zhang WW, Qiu YT, Ke LF, Chen H, Chen G (2023) PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics. Histopathology 82:285\u2013295. https:\/\/doi.org\/10.1111\/his.14814","journal-title":"Histopathology"},{"key":"3606_CR16","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/dad.0000000000001885","volume":"43","author":"PB Googe","year":"2021","unstructured":"Googe PB, Flanigan KL, Miedema JR (2021) Preferentially expressed antigen in melanoma immunostaining in a series of melanocytic neoplasms. Am J Dermatopathol 43:794\u2013800. https:\/\/doi.org\/10.1097\/dad.0000000000001885","journal-title":"Am J Dermatopathol"},{"key":"3606_CR17","doi-asserted-by":"publisher","first-page":"675296","DOI":"10.3389\/fonc.2021.675296","volume":"11","author":"G Ferrara","year":"2021","unstructured":"Ferrara G, Argenziano G (2021) The WHO 2018 classification of cutaneous melanocytic neoplasms: suggestions from routine practice. Front Oncol 11:675296. https:\/\/doi.org\/10.3389\/fonc.2021.675296","journal-title":"Front Oncol"},{"key":"3606_CR18","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.3390\/cancers13153864","volume":"13","author":"M Gassenmaier","year":"2021","unstructured":"Gassenmaier M, Hahn M, Metzler G et al (2021) Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas. Cancers 13:3864. https:\/\/doi.org\/10.3390\/cancers13153864","journal-title":"Cancers"},{"key":"3606_CR19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/dad.0000000000002208","volume":"44","author":"P Gerami","year":"2022","unstructured":"Gerami P, Benton S, Zhao J et al (2022) PRAME expression correlates with genomic aberration and malignant diagnosis of spitzoid melanocytic neoplasms. Am J Dermatopathol 44:575\u2013580. https:\/\/doi.org\/10.1097\/dad.0000000000002208","journal-title":"Am J Dermatopathol"},{"key":"3606_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/PAS.0000000000001645","volume":"45","author":"A Agaimy","year":"2021","unstructured":"Agaimy A, Stoehr R, Hornung A et al (2021) Dedifferentiated and undifferentiated melanomas: report of 35 new cases with literature review and proposal of diagnostic criteria. Am J Surg Pathol 45:240\u2013254. https:\/\/doi.org\/10.1097\/PAS.0000000000001645","journal-title":"Am J Surg Pathol"},{"key":"3606_CR21","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/jnen\/nlaa125","volume":"80","author":"CR Cadwell","year":"2021","unstructured":"Cadwell CR, Yuksek GE, Hirbe AC et al (2021) Preferentially expressed antigen in melanoma (PRAME) expression in malignant, but not benign, peripheral nerve sheath tumors. J Neuropathol Exp Neurol 80:384\u2013386. https:\/\/doi.org\/10.1093\/jnen\/nlaa125","journal-title":"J Neuropathol Exp Neurol"},{"key":"3606_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/cup.14163","volume":"49","author":"AM Cesinaro","year":"2022","unstructured":"Cesinaro AM, Piana S, Paganelli A, Pedroni G, Santandrea G, Maiorana A (2022) PRAME expression in cellular neurothekeoma: a study of 11 cases. J Cutan Pathol 49:338\u2013342. https:\/\/doi.org\/10.1111\/cup.14163","journal-title":"J Cutan Pathol"},{"key":"3606_CR23","volume-title":"Soft tissue and bone tumours 5th edn","author":"WHO Classification of Tumours editorial board","year":"2020","unstructured":"WHO Classification of Tumours editorial board (2020) Soft tissue and bone tumours 5th edn. International Agency for Research on Cancer, Lyon, France"},{"key":"3606_CR24","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.3390\/cancers12123612","volume":"12","author":"M Albertsmeier","year":"2020","unstructured":"Albertsmeier M, Altendorf-Hofmann A, Lindner LH et al (2020) Cancer testis antigens and immunotherapy: expression of PRAME is associated with prognosis in soft tissue sarcoma. Cancers 12:3612. https:\/\/doi.org\/10.3390\/cancers12123612","journal-title":"Cancers"},{"key":"3606_CR25","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/his.14797","volume":"81","author":"SM Hrycaj","year":"2022","unstructured":"Hrycaj SM, Szczepanski J, Zhao L et al (2022) PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumor, and other cutaneous sarcomatoid neoplasms: a comparative analysis. Histopathology 81:818\u2013825. https:\/\/doi.org\/10.1111\/his.14797","journal-title":"Histopathology"},{"key":"3606_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.humpath.2016.12.006","volume":"61","author":"K Iura","year":"2017","unstructured":"Iura K, Maekawa A, Kohashi K et al (2017) Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. Hum Pathol 61:130\u2013139. https:\/\/doi.org\/10.1016\/j.humpath.2016.12.006","journal-title":"Hum Pathol"},{"key":"3606_CR27","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1177\/10668969211012085","volume":"29","author":"C Lezcano","year":"2021","unstructured":"Lezcano C, M\u00fcller AM, Frosina D et al (2021) Immunohistochemical detection of cancer-testis antigen PRAME. Int J Surg Pathol 29:826\u2013835. https:\/\/doi.org\/10.1177\/10668969211012085","journal-title":"Int J Surg Pathol"},{"key":"3606_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/gcc.22254","volume":"54","author":"L Wang","year":"2015","unstructured":"Wang L, Zehir A, Sadowska J et al (2015) Consistent copy number changes and recurrent PRKAR1A mutations distinguish melanotic schwannomas from melanomas: SNP-array and next generation sequencing analysis. Genes Chromosom Cancer 54:463\u2013471. https:\/\/doi.org\/10.1002\/gcc.22254","journal-title":"Genes Chromosom Cancer"},{"key":"3606_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/gcc.20827","volume":"50","author":"T Guo","year":"2011","unstructured":"Guo T, Zhang L, Chang NE, Singer S, Maki RG, Antonescu CR (2011) Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosom Cancer 50:25\u201333. https:\/\/doi.org\/10.1002\/gcc.20827","journal-title":"Genes Chromosom Cancer"},{"key":"3606_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/cjp2.16","volume":"1","author":"K Iura","year":"2015","unstructured":"Iura K, Kohashi K, Hotokebuchi Y et al (2015) Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. J Pathol Clin Res 1:144\u2013159. https:\/\/doi.org\/10.1002\/cjp2.16","journal-title":"J Pathol Clin Res"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-023-03606-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-023-03606-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-023-03606-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T10:19:08Z","timestamp":1691576348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-023-03606-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["3606"],"URL":"https:\/\/doi.org\/10.1007\/s00428-023-03606-6","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"26 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted following local ethical guidelines; cases are recorded in the French expert sarcoma network (NetSarc+) database, approved by the National Committee for Protection of Personal Data (CNIL, no. 910390).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}